What is the recommended management for ductal carcinoma in situ that is estrogen‑receptor negative, progesterone‑receptor negative, and HER‑2 2+ (equivocal)?

Management of ER-Negative, PR-Negative, HER2 2+ DCIS

For this triple-negative DCIS with equivocal HER2, proceed with surgical excision (breast-conserving surgery or mastectomy based on disease extent) followed by radiation therapy if breast-conserving surgery is performed; do not offer endocrine therapy, and confirm HER2 status with FISH/CISH testing to guide surveillance strategies.

Immediate Diagnostic Step: Clarify HER2 Status

• Perform FISH or CISH testing immediately to determine true HER2 amplification status, as HER2 2+ by immunohistochemistry is equivocal and requires reflex testing for definitive classification 1.
• This distinction matters because HER2-positive DCIS shows higher recurrence rates and may influence surgical planning, though it does not change immediate treatment recommendations for DCIS 2, 3, 4.

Surgical Management Algorithm

Breast-Conserving Surgery Candidates

• Offer lumpectomy without lymph node surgery if the DCIS is localized, ≤4 cm in extent, without multicentric disease or diffuse malignant calcifications 1, 5.
• Achieve margins ≥2 mm through re-excision if necessary, as inadequate margins significantly increase recurrence risk (HR 2.25,95% CI 1.77-2.86) 5, 3.
• All malignant-appearing microcalcifications must be completely removed before considering breast conservation 1.

Mastectomy Indications

• Perform mastectomy with optional sentinel node biopsy if any of the following are present 1, 6:
  • Two or more primary tumors in different breast quadrants (multicentric disease)
  • Diffuse malignant-appearing microcalcifications throughout the breast
  • Persistently positive margins after reasonable re-excision attempts
  • Large tumor-to-breast size ratio where adequate excision would cause unacceptable cosmetic deformity
  • Patient preference after informed discussion

Radiation Therapy Decision

• Administer whole-breast radiation therapy after breast-conserving surgery as this reduces both in situ and invasive recurrence risk across all DCIS subtypes, including hormone receptor-negative disease 1, 5.
• The benefit of radiation is particularly pronounced in ER-negative DCIS, as these patients cannot benefit from endocrine therapy for risk reduction 7.
• Omit radiation only in highly selected circumstances: women >70 years with low-risk features (small size, low grade, wide margins >10 mm) may consider surgery alone, though this is category 2B evidence 1, 5.

Endocrine Therapy: Contraindicated

• Do not offer tamoxifen or aromatase inhibitors to this patient, as ER-negative and PR-negative DCIS derives no benefit from endocrine therapy and may experience harm from unnecessary side effects 1, 5.
• The NSABP B-24 trial demonstrated that tamoxifen reduces recurrence only in hormone receptor-positive DCIS 1.
• This represents a critical pitfall: approximately 30% of DCIS cases are hormone receptor-negative, and these patients should never receive endocrine therapy 5.

Prognostic Considerations Based on Receptor Status

• ER-negative, PR-negative DCIS carries distinct biological behavior compared to hormone receptor-positive disease, with potentially higher local recurrence rates (9.7% in one series at median 5.3 years follow-up) 7.
• If HER2 testing confirms amplification (HER2 3+ or FISH-positive), this further increases recurrence risk (HR 1.71-1.81 for various adverse features) and strongly supports the use of adjuvant radiation 2, 3, 4.
• The ER-negative/PR-negative/HER2-positive receptor pattern represents 50% of total recurrences in some series, with significantly shorter disease-free survival 4.

Surveillance Strategy

• Perform clinical breast examination every 6-12 months for 5 years, then annually 1.
• Annual bilateral mammography is mandatory, as contralateral breast cancer risk persists even in hormone receptor-negative disease 7.
• If HER2 is confirmed positive by FISH/CISH, consider more intensive surveillance given the 2-3 fold increased recurrence risk 2, 3.

Critical Pitfalls to Avoid

• Never perform complete axillary lymph node dissection for pure DCIS without documented invasive disease or proven axillary metastases 1, 6.
• Do not base surgical decisions solely on MRI findings without histologic confirmation, as MRI overestimates disease extent in 20-30% of cases 6.
• Never offer endocrine therapy based on HER2 status alone when hormone receptors are negative—HER2-targeted therapy (trastuzumab) has no established role in pure DCIS 1, 5.
• Recognize that approximately 25% of biopsy-diagnosed "pure DCIS" will have invasive cancer at definitive surgery, particularly in HER2-positive cases, which may necessitate axillary staging 6, 2.